Gomisin G
Based on 2 publication(s) in Google Scholar
Gomisin G is a lignin from S. chinesis with anti-HIV (EC50 = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 62956-48-3
- Formule: C30H32O9
- Masse moléculaire:536.57
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
-
Antiviral Compound Library
HY-L027
Publications Citing Use of MedChemExpress (MCE) Gomisin G
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H9 | EC50 |
0.011 μM
Compound: 125
|
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
|
[PMID: 20187635] |
| HL-60 | IC50 |
38.2 μM
Compound: 12
|
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
|
[PMID: 16562834] |
| HL-60 | IC50 |
48.3 μM
Compound: 12
|
Cytotoxicity against human HL60 cells by XTT assay
Cytotoxicity against human HL60 cells by XTT assay
|
[PMID: 16562834] |
Gomisin G (1-10 μM, 3-5 d) significantly inhibits the growth of LoVo cells in a dose and time dependent manner[2].
Gomisin G (10 μM, 24 h) significantly reduces the phosphorylation level of AKT and induces apoptosis in LoVo cells[2].
Gomisin G (10 μM, 72 h) leads to a significantly higher population at the sub-G1 phase and decreased population of cells in G1 and G2M phase of the cell cycle[2].
Gomisin G (1-10 μM, 3-5 d) selectively reduces the growth of MDA-MB-231 and MDA-MB-468 cells (TNBC cells) but not other breast cancer cell lines[3].
Gomisin G (10 μM, 72 h) significantly decreases the cyclin D1 level in the MDA-MB-231 cells[3].
Gomisin G (0-10 μM, 24 h) suppresses the expression of muscle degradation factors but increases the muscle synthesis rate in H2O2-treated C2C12 myotubes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LoVo cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Elicited PARP cleavage.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Disuse-induced muscle atrophic C57BL/6N mice[4]
-
Dosage:1 mg/kg/day
-
Administration:Oral gavage (p.o.) for 2 weeks
-
Result:Inhibited protein degradation but increased protein synthesis.
Significantly reduced mTOR phosphorylation.
Induced a switch in muscle fiber content from fast-type glycolytic fibers to slow-type oxidative fibers.
Induced mitochondrial biogenesis in the skeletal muscle via the Sirt 1/PGC-1α signaling pathway.
Chemical Information
-
CAS No. 62956-48-3
-
Appearance Solid
-
Masse moléculaire 536.57
-
Formule C30H32O9
-
Color White to off-white
-
SMILES
COC1=C(OCO2)C2=CC([C@H](OC(C3=CC=CC=C3)=O)[C@](O)(C)[C@@H](C)C4)=C1C(C4=CC(OC)=C5OC)=C5OC
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Biochem Biophys Res Commun
Gomisin J inhibits the glioma progression by inducing apoptosis and reducing HKII-regulated glycolysis. [Abstract]2020 Aug 13;529(1):15-22. PMID: 32560813
Solvant et solubilité
DMSO : ≥ 50 mg/mL (93.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Chen DF, et al. Anti-AIDS agents--XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogues. Bioorg Med Chem. 1997 Aug;5(8):1715-23. [Content Brief]
[2]. Maharjan, S., et al., (2019). Gomisin G Suppresses the Growth of Colon Cancer Cells by Attenuation of AKT Phosphorylation and Arrest of Cell Cycle Progression. Biomolecules & therapeutics, 27(2), 210–215. [Content Brief]
[3]. Maharjan, S., et al., (2018). Gomisin G Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing AKT Phosphorylation and Decreasing Cyclin D1. Biomolecules & therapeutics, 26(3), 322–327. [Content Brief]
[4]. Yeon, M., et al., (2022). Gomisin G improves muscle strength by enhancing mitochondrial biogenesis and function in disuse muscle atrophic mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 153, 113406. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8637 mL | 9.3184 mL | 18.6369 mL | 46.5922 mL |
| 5 mM | 0.3727 mL | 1.8637 mL | 3.7274 mL | 9.3184 mL | |
| 10 mM | 0.1864 mL | 0.9318 mL | 1.8637 mL | 4.6592 mL | |
| 15 mM | 0.1242 mL | 0.6212 mL | 1.2425 mL | 3.1061 mL | |
| 20 mM | 0.0932 mL | 0.4659 mL | 0.9318 mL | 2.3296 mL | |
| 25 mM | 0.0745 mL | 0.3727 mL | 0.7455 mL | 1.8637 mL | |
| 30 mM | 0.0621 mL | 0.3106 mL | 0.6212 mL | 1.5531 mL | |
| 40 mM | 0.0466 mL | 0.2330 mL | 0.4659 mL | 1.1648 mL | |
| 50 mM | 0.0373 mL | 0.1864 mL | 0.3727 mL | 0.9318 mL | |
| 60 mM | 0.0311 mL | 0.1553 mL | 0.3106 mL | 0.7765 mL | |
| 80 mM | 0.0233 mL | 0.1165 mL | 0.2330 mL | 0.5824 mL |
Gomisin G Related Classifications
HY-N0858 Related Classifications
Powered by Bioz